Approaches to informed consent for hypothesis-testing and hypothesis-generating clinical genomics research by unknown
Facio et al. BMC Medical Genomics 2012, 5:45
http://www.biomedcentral.com/1755-8794/5/45DEBATE Open AccessApproaches to informed consent for
hypothesis-testing and hypothesis-generating
clinical genomics research
Flavia M Facio1, Julie C Sapp1, Amy Linn1,2 and Leslie G Biesecker1*Abstract
Background: Massively-parallel sequencing (MPS) technologies create challenges for informed consent of research
participants given the enormous scale of the data and the wide range of potential results.
Discussion: We propose that the consent process in these studies be based on whether they use MPS to test a
hypothesis or to generate hypotheses. To demonstrate the differences in these approaches to informed consent,
we describe the consent processes for two MPS studies. The purpose of our hypothesis-testing study is to elucidate
the etiology of rare phenotypes using MPS. The purpose of our hypothesis-generating study is to test the feasibility
of using MPS to generate clinical hypotheses, and to approach the return of results as an experimental
manipulation. Issues to consider in both designs include: volume and nature of the potential results, primary versus
secondary results, return of individual results, duty to warn, length of interaction, target population, and privacy and
confidentiality.
Summary: The categorization of MPS studies as hypothesis-testing versus hypothesis-generating can help to clarify
the issue of so-called incidental or secondary results for the consent process, and aid the communication of the
research goals to study participants.
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Advances in DNA sequencing technologies and con-
comitant cost reductions have made the use of
massively-parallel sequencing (MPS) in clinical research
practicable for many researchers. Implementations of
MPS include whole genome sequencing and whole
exome sequencing, which we consider to be the same,
for the purposes of informed consent. A challenge for
researchers employing these technologies is to develop
appropriate informed consent [1,2], given the enormous
amount of information generated for each research par-
ticipant, and the wide range of medically-relevant gen-
etic results. Most of the informed consent challenges
raised by MPS are not novel – what is novel is the scale
and scope of genetic interrogation, and the opportunity
to develop novel clinical research paradigms.* Correspondence: leslieb@helix.nih.gov
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reproduction in any medium, provided the orMassively-parallel sequencing has the capacity to detect
nearly any disease-causing gene variant, including late-
onset disorders, such as neurologic or cancer-susceptibility
syndromes, subclinical disease or endo-phenotypes, such as
impaired fasting glucose, and heterozygous carriers of traits
inherited in a recessive pattern. Not only is the range of the
disorders broad, but the variants have a wide range of
relative risks from very high to nearly zero. This is a key
distinction of MPS when compared to common SNP
variant detection (using so-called gene chips). Because
some variants discovered by MPS can be highly pene-
trant, the detection of such variants can have enormous
medical and counseling impact. While many of these
informed consent issues have been addressed previously
[1,3], the use of MPS in clinical research combines these
issues and is on a scale that is orders of magnitude
greater than previous study designs.
The initial clinical research uses of MPS were a brute
force approach to the identification of mutations for rare
mendelian disorders [4]. This is a variation of positionaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of classical hypothesis-testing research. The hypothesis
is that the phenotype under study is caused by a genetic
variant and a suite of techniques is employed (in this
case MPS) to identify that causative variant. The applica-
tion of this technology in this setting is of great promise
and will identify causative gene variants for numerous
traits, with some predicting that the majority of Mendelian
disorders will be elucidated in 5–10 years.
The second of these pathways to discovery is a more
novel approach of generating and then sifting MPS results
as the raw material to allow the generation of clinical hy-
potheses, which are in turn used to design clinical experi-
ments to discover the phenotype that is associated with
that genotype. This approach we term hypothesis-
generating clinical genomics. These hypothesis-generating
studies require a consent process that provides the partici-
pant with an understanding of scale and scope of the in-
terrogation, which is based on a contextual understanding
of the goal and overall organization of the research since
specific risks and benefits can be difficult to delineate
[5,6]. Importantly, participants need to understand the no-
tion that the researcher is exploring their genomes in an
open-ended fashion, that the goal of the experiment is not
predictable at the outset, and that the participant will be
presented with downstream situations that are not cur-
rently foreseeable.
We outline here our approaches to informed consent
for our hypothesis-testing and hypothesis-generating
MPS research studies. We propose that the consent
process be tailored depending on which of these two
designs is used, and whether the research aims include
study of the return of results.
General issues regarding return of results
Participants in our protocols have the option to learn
their potentially clinically relevant genetic variant results.
The issue of return of results is controversial and the
theoretical arguments for and against the return of
results have been extensively debated [7]. Although an
increasing body of literature describes the approaches
taken by a few groups no clear consensus exists in either
the clinical genomics or bioethics community [8]. At
one end of the spectrum there are those who argue that
no results should be returned [9], and at the other end
others contend that the entire sequence should be pre-
sented to the research participant [10-12]. In between
these extremes lies a qualified or intermediate disclosure
policy [13,14]. We take the intermediate position in both
of our protocols by giving research participants the
choice to receive results, including variants deemed
to be clinically actionable [3,15]. Additionally, both
protocols are investigating participants’ intentions to-
wards receiving different types of results in order toinform the disclosure policies within the projects and in
the broader community [16]. Because one of our re-
search goals is to study the issues surrounding return of
results, it is appropriate and necessary to return results.
Thus, the following discussion focuses on issues pertin-
ent to studies that plan to return results.Issues to consider
Issue #1: Primary versus secondary variant results and the
open-ended nature of clinical genomics
In our hypothesis-testing study we distinguish variants
as either primary or secondary variants, the distinction
reflecting the purpose of the study. A primary variant is
a mutation that causes the phenotype that is under
study, i.e., the hypothesis that is being tested in the
study. A secondary variant is any mutation result not
related to the disorder under study, but discovered as
part of the quest for the primary variant.
We prefer the term ‘secondary’ to ‘incidental’ because
the latter is an adjective indicating chance occurrence,
and the discovery of a disease causing mutation by MPS
cannot be considered a chance occurrence. The word
‘incidental’ also suggests a lesser degree of importance or
impact and it is important to recognize that secondary
findings can be of greater medical or personal impact
than primary findings.
The consent discussion about results potentially avail-
able from participation in a hypothesis-testing study is
framed in terms of the study goal, and we assume a high
degree of alignment between participants’ goals and the
researchers’ aims with respect to primary variants. Parti-
cipants are, in general, highly motivated to learn the pri-
mary variant result and we presume that this motivation
contributed to their decision to enroll in the study, simi-
lar to motivations for those who have been involved in
positional cloning studies. This motivation may not hold
for secondary variants, but our approach is to offer them
the opportunity to learn secondary and actionable var-
iants that may substantially alter susceptibility to, or re-
productive risk for, disease.
In the hypothesis-generating study design no categor-
ical distinction (primary vs. secondary) is made among
pathogenic variants, i.e., all variants are treated the same
without the label of ‘primary’ or ‘secondary’. This is be-
cause we are not using MPS to uncover genetic variants
for a specific disease, and any of the variants could po-
tentially be used for hypothesis generation. We suggest
that this is the most novel issue with respect to informed
consent as the study is open-ended regarding its goals
and downstream research activities. This is challenging
for informed consent because it is impossible to know
what types of hypotheses may be generated at the time of
enrollment and consent.
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are impossible to predict in hypothesis-generating re-
search, subjects must be consented initially to the open-
ended nature of the project. During the course of the
study, they must be iteratively re-consented as hypoth-
esis are generated from the genomic data and more spe-
cific follow-up studies are designed and proposed to test
those newly generated hypotheses. These downstream,
iterative consents will vary in their formality, and the de-
gree to which they need to be reviewed and approved.
Some general procedures can be approved in advance;
for example it may be anticipated that segregation stud-
ies would be useful to determine causality for sequence
variants or the investigator may simply wish to obtain
some additional targeted medical or family history from
the research subject. This could be approved prospect-
ively by the IRB with the iterative consent with the sub-
ject comprising a verbal discussion of the nature of the
trait for which the segregation analysis or additional in-
formation is being sought. More specific or more inva-
sive or risky iterative analyses would necessitate review
and approval by the IRB with written informed consent.
Informed consent approach The informed consent
process must reflect the fundamental study design dis-
tinction of hypothesis-testing versus hypothesis-
generating clinical genomics research. For the latter, the
challenge is to help the research subjects understand
that they are enrolling in a study that could lead to
innumerable downstream research activities and goals.
The informed consent process must be, like the re-
search, iterative, and involve ongoing communication
and consent with respect to those downstream activities.
Issue #2: Volume and nature of information
Whole genome sequencing can elucidate an enormous
number of variations for a given individual. A typical
whole genome sequence yields ~4,000,000 sequence var-
iations. A whole exome sequence limits the interrogation
to the coding regions of genes (about 1–1.5% of the gen-
ome) and generates typically 30,000-50,000 gene variants.
While most are benign or of unknown consequence,
some are associated with a significant increased risk of
disease for the individual and/or their family members.
For example, the typical human is a carrier for three to
five deleterious genetic variants or mutations that cause
severe recessive diseases [17,18]. In addition, there are
over 30 known cancer susceptibility syndromes, which in
aggregate may affect more than 1/500 patients, and the
sequence variants that cause these disorders can be read-
ily detected with MPS. These variants can have extremely
high relative risks. For some disorders, a rare variant can
be associated with a relative risk of greater than 1,000.
This is in contrast with common SNP typing whichdetects variants associated with small relative risks (typ-
ically on the order of 1.2-1.5). It is arguable whether
the latter type of variant has any clinical utility as an
individual test.
Conveying the full scope of genomic interrogation
planned for each sample and the volume of information
generated for a given participant is impossible. The goal
and challenge in this instance is to give the participant
as realistic a picture as possible of the likely amount of
clinically actionable results the technology can generate.
Our approach is two-fold: to give the subjects the clear
message that the number and nature of the findings is
enormous and literally impossible to describe in a com-
prehensive manner and to use illustrative examples of
the spectrum of these results.
To provide examples, we bin genetic variants into
broad categories, as follows: heterozygous carriers of
genetic variants implicated in recessive conditions (e.g.,
CFTR p.Phe508del and cystic fibrosis); variants that
cause a treatable disorder that may be present, but
asymptomatic or undiagnosed (e.g., LDLR p.Trp87X,
familial hypercholesterolemia); variants that predispose
to later-onset conditions (e.g., BRCA2 c.5946delT
(commonly known as c.6174delT), breast and ovarian
cancer susceptibility); variants that predispose to late-
onset but untreatable disorders (e.g., frontotemporal
dementia MAPT p.Pro301Leu).
Additionally, the scale and scope of the results deter-
mines a near certainty that all participants will be found
to harbor disease-causing mutations. This is because the
interrogation of all genes brings to light the fact that the
average human carries 3–5 recessive deleterious genes in
addition to the risks for later onset or incompletely
penetrant dominant disorders. This reality can be unset-
tling and surprising to research subjects and we believe
it is important to address this early in the process, not
downstream in the iterative phase. It is essential for the
participants to choose whether MPS research is appro-
priate for them, taking into account their personal views
and values.
Informed consent approach Communicate to partici-
pants both the overwhelming scale and scope of genetic
results they may opt to receive and provide them with
specific disease examples that illustrate the kinds of deci-
sions they may need to make as the results become avail-
able. These examples should also assist the research
subjects in making a decision about whether to participate
in the study and if so, the kinds of decisions they may
need be making in the future as results become available.
Issue #3: Return of individual genotype results
The return of individual genotype results from MPS pre-
sents a new challenge in the clinical research environment,
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The genetic and medical counseling can be challenging
because of the volume of results generated, participants’
expectations, the many different categories of results,
and the length of time for the information to be avail-
able. We suggest that the most reasonable practice is to
take a conservative approach and disclose only clinically
actionable results. To this end, the absence of a deleteri-
ous gene variant (or a negative result) would not be dis-
closed to research participants. It is our understanding
that it is mandatory to validate any individual results
that are returned to research subjects in a CLIA-
certified laboratory. Using current clinical practice as a
standard or benchmark, we suggest that until other
approaches are shown to be appropriate and effective,
disclosure should take place during a face-to-face en-
counter involving a multidisciplinary team (geneticist,
genetic counselor, and specialists on an ad-hoc basis
based on the phenotype in question).
During the initial consent, participants are alerted to
the fact that in the future the study team will contact
them by telephone and their previously-stated prefer-
ences and impressions about receiving primary and sec-
ondary variant results will be reviewed. The logistics
and details of this future conversation feature promin-
ently in the initial informed consent session, as it is
challenging to make and to receive such calls. Partici-
pants make a choice to learn or not learn a result each
time a result becomes available. Once a participant
makes the decision to learn a genotype result, the vari-
ant is confirmed in a CLIA lab, and a report is gener-
ated. The results are communicated to the participant
during a face-to-face meeting with a geneticist and gen-
etic counselor, and with the participation of other spe-
cialists depending on the case and the participant’s
preferences. These phone discussions are seen as an ex-
tension of the initial informed consent process and as
opportunities for the participants to make decisions in
a more relevant and current context (compared to the
original informed consent session). We see this as an it-
erative approach to consent, also known as circular
consent [5]. Participants who opt not to learn a specific
result can still be contacted later if other results be-
come available, unless they choose not to be contacted
by us any longer.
This approach to returning results is challenged by the
hypothesis-generating genomics research approach. Par-
ticipants in our hypothesis-testing protocol are not
asked to make a decision about learning individual geno-
type results at the time of consent. This is because we
cannot know the nature of the future potential finding at
the time of the original consent. Rather, they are
engaged in a discussion of what they currently imagine
their preferences might be at some future date, againusing exemplar disorders and hypothetical scenarios of
hypothesis-generating studies.
In the hypothesis-generating study, we have distinct
approaches for variants in known disease-causing genes
versus variants in genes that are hypothesized to cause
disease (the latter being the operative hypothesis gener-
ating activity). For the former, the results are handled in
a manner quite similar to the hypothesis-testing study.
In the latter case, the participant may be asked if they
would be willing to return for further phenotyping to
help us determine the nature of the variant of uncertain
clinical significance (VUCS). The participant is typically
informed that they have a sequence variant and that we
would like to learn, through clinical research whether
this variant has any phenotypic or clinical significance. It
is emphasized that current knowledge does not show
that the variant causes any phenotype and the chances
are high that the variant is benign. However, neither the
gene nor the sequence variant is disclosed and the re-
search finding is not confirmed in a CLIA certified lab.
This type of VUCS would only be communicated back
to the participant if the clinical research showed that the
variant was causative, and the return of the result was
determined medically appropriate by our Mutation Ad-
visory Committee, and following confirmation in a
CLIA-certified laboratory.
Informed consent approach For the return of muta-
tions in known, disease causing genes, the initial consent
cannot comprehensively inform subjects of the nature of
the diseases, because of the scale and scope of the po-
tential results. Instead, exemplars are given to elicit gen-
eral preferences, which are then affirmed or refined at
the time results are available. Hypothesis-generating
studies require that subjects receive sufficient informa-
tion to make an informed choice about participation in
the specific follow-up study, with return of individual
results only if the cause and effect relationship is estab-
lished, with appropriate oversight.
Issue #4: Duty to warn
Given the breadth of MPS gene interrogation, it is rea-
sonable to anticipate that occasional participants may
have mutations that pose a likely severe negative
consequence, which we classify as “panic” results. This
models clinical and research practice for the return of
results such as a pulmonary mass or high serum potas-
sium level. In contrast to the above-mentioned auto-
somal recessive carrier states that are expected to be
nearly universal, genetic panic results should be uncom-
mon. However, they should not be considered as
unanticipated – it is obvious that such variants will be
detected and the informed consent process should
anticipate these. Examples would be deleterious variants
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ther of which have a substantial risk of sudden death
and the risk can be mitigated.
Both our hypothesis-testing and hypothesis-generating
studies include mechanisms for the participants to indi-
cate the types of results that they wish to have returned
to them. In the hypothesis-testing mode of research this
is primarily to respect the autonomy of the participants,
but in addition, for the hypothesis-generating study we
are assessing the motivations and interests of the sub-
jects in various types of results and manipulating the re-
turn of results as an experimental aim. It is our clinical
research experience that participants are challenged by
making decisions regarding possible future results that
are rare, but potentially severe. As well, the medical and
social contexts of the subjects evolves over time and the
consent that was obtained at enrollment may not be
relevant or appropriate at a later time when such a result
arises. This is particularly relevant for a research study
that is ongoing for substantial periods of time (see also
point #7, below).
To address these issues we have consented the subjects
to the potential return of “panic” results, irrespective of
their preferences at the initial consent session. In effect,
the consent process is for some participants a consent to
override their preference.
Informed consent approach In both hypothesis-testing
and hypothesis-generating research it is important to
outline circumstances in which researchers’ duty-to-
warn may result in a return of results that may be con-
trary to the preferences of the subject. It is essential that
the subjects understand this approach to unusually se-
vere mutation results. Subjects who are uncomfortable
with this approach to return of results are encouraged to
decline enrollment.
Issue #5: Length of researcher and participant interaction
Approaches to MPS data are evolving rapidly and it is
anticipated that this ongoing research into the signifi-
cance of DNA variants will continue for years or dec-
ades. The different purposes of the two study designs
lead to different endpoints in terms of researcher’s re-
sponsibility to analyze results. In our hypothesis-testing
research, discussion of the relationship of the partici-
pants to the researchers is framed in terms of the dis-
covery of the primary variant. We ask participants to be
willing to interact with us for a period of months or
years as it is impossible for to set a specific timeline to
determine the cause of the disorder under investigation
(if it ever discovered). While attempts to elucidate the
primary variant are underway, participants’ genomic data
are periodically annotated using the most current bio-
informatic methodologies available. We conceptualizeour commitment to return re-annotated and updated
results to participants as diminishing, but not disappear-
ing, after this initial results’ disclosure. As the primary
aim of the study has been accomplished, less attention
will be directed to the characterization of ancillary gen-
omic data, yet we believe we retain an obligation to
share highly clinically actionable findings with partici-
pants should we obtain them.
In the hypothesis-generating study the researcher’s re-
sponsibility to annotate participants’ genomes/exomes is
ongoing. This is ongoing because, as noted above, one of
the experimental aims is to study the motivations and
interests of the subjects in these types of results. Deter-
mining how this motivation and interest fares over time
is an important research goal. During the informed con-
sent discussion it is emphasized that the iterative nature
of result interpretation will lead to multiple meetings for
the disclosure of clinically actionable results, and that
the participant may be contacted months or years after
the date of enrollment. Additionally, it is outlined that
the participant will make a choice about learning the re-
sult each time he/she is re-contacted about the availabil-
ity of a research finding, and that finding will only be
confirmed in a CLIA-certified laboratory if the partici-
pant opts to learn the information. Participants who re-
turn to discuss results are reminded that they will be
contacted in the future if and when other results deemed
to be clinically actionable are found for that individual.Informed consent approach Describe nature, mutual
commitments, and duration of researcher-participant re-
lationship to participants. For hypothesis-testing studies
it is appropriate that the intensity of the clinical annota-
tion of secondary variants may decline when the primary
goal of the study is met. For hypothesis-generating stud-
ies, such interactions may continue for as long as there
are variants to be further evaluated and as long as the
subject retains an interest in the participation.Issue #6: Target population
The informed consent process needs to take into account
the target population in terms of their disease phenotype,
age, and whether the goal is to enroll individual partici-
pants or families. These considerations represent the
greatest divergence in approaches to informed consent
when comparing hypothesis-testing and hypothesis-
generating research. In our two studies, the hypothesis-
testing study focuses on rare diseases and often family
participation, whereas the hypothesis-generating study
focuses on more common diseases and unrelated index
cases. There are an infinite number of study designs and
investigators may adapt our approaches to informed con-
sent for their own designs.
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participants and families (most commonly trios), the lat-
ter being more common. In hypothesis-testing research,
many participants are either affected by a genetic disease
or are a close relative (typically a parent) of a person
with a genetic disease. The research participants must
weigh their hope for, and personal meaning ascribed to,
learning the genetic cause for their disorder against the
possibility of being in a position to learn a significant
amount of unanticipated information. Discussing and
addressing the potential discrepancy of the participants’
expectations of the value of their results and what they
may realistically stand to learn (both desired and un-
desired information) is a central component of the
informed consent process.
In our hypothesis-testing protocol, when parents are
consenting on behalf of a minor child, we review with
them the issues surrounding genetic testing of children
and discuss their attitudes regarding their child’s auton-
omy and their parental decision-making values. Because
family trios (most often mother-father-child) are en-
rolled together, we discuss how one individual’s prefer-
ences regarding results may be disrupted or superseded
by another family member’s choice and communication
of that individual’s knowledge.
In contrast, our hypothesis-generating protocol enrolls
as probands or primary participants older, unrelated
individuals [19]. Most participants are self-selected in
terms of their decision to enroll and are not enrolled be-
cause they or a relative have a rare disease. Participants
in the hypothesis-generating protocol are consented for
future exploration of any and all possible phenotypes.
This is a key distinguishing feature of this hypothesis-
generating approach to research, which is a different
paradigm – going from genotype to phenotype. The par-
ticipants may be invited for additional phenotyping. In
fact, multiple satellite studies are ongoing to evaluate
various subsets of participants for different phenotypes.
The key with the consent for these subjects is to initially
communicate to the subjects the general approach –
that their genome will be explored, variations will be
identified, and they may be re-contacted for a potential
follow-up study to understand the potential relationship
of that variant to their phenotype. These subsequent
consents for follow-up studies are considered an itera-
tive consent process, which is similar to the Informed
Cohort concept [20].
Informed consent approach Hypothesis-generating re-
search is a novel approach to clinical research design
and requires an ongoing, iterative approach to informed
consent. For hypothesis-testing research a key informed
consent issue is for the subjects to balance the desire for
information on the primary disease causing mutationwith the pros and cons of obtaining possibly undesired
information on secondary variants.
Issue #7: Privacy and confidentiality
In MPS studies, privacy and confidentiality is a complex
and multifaceted issue. Some potential challenges in-
clude: the deposition of genetic and phenotypic data in
public databases, the placement of CLIA-validated results
in the individual’s medical chart, and the discovery of
secondary variants in relatives of affected probands in
family-based (typically hypothesis-testing) research.
The field of genomics has a tradition of deposition of
data in publicly accessible databases. Participants in our
protocols are informed that the goal of sharing de-
identified information in public databases is to advance
research, and that there are methods in place maximize
the privacy and confidentiality of personally identifiable
information. However, the deposition of genomic-scale
data for an individual participant, such as a MPS se-
quence, is far above the minimal amount of data to
uniquely identify the sample [21,22]. Therefore, the par-
ticipants should be made aware that the scale of the data
could allow analysts to connect sequence data to indivi-
duals by matching variants in the deposited research
data to other data from that person. As well, the public
deposition of data in some cases is an irrevocable deci-
sion. Once the data are deposited and distributed, it
may be impossible to remove the data from all com-
puter servers, should the subject decide to withdraw
from the study.
Additionally, participants are informed that once a re-
sult is CLIA-certified, that result is placed in the indivi-
dual’s medical chart of the clinical research institution
and may be accessible by third parties. Although there
are state and federal laws to protect individuals against
genetic discrimination, including GINA, this law has not
yet been tested in the courts. This is explained to partici-
pants up front at the time of enrollment and a more
detailed discussion takes place at the time of results dis-
closure. To offer additional protection in the event of a
court subpoena, a Certificate of Confidentiality has been
obtained in the hypothesis-testing and hypothesis-
generating protocols. The discussion surrounding priv-
acy and confidentiality is approached in a similar man-
ner in both protocols.
The third issue regarding confidentiality is that MPS
can generate many results in each individual and it is
highly likely that some, if not all, of the variants detected
in one research participant may be present in another
research participant (e.g., a parent). This is again a con-
sequence of the scale and breadth of MPS in that the
large number of variants that can be detected in each
participant makes it exceedingly likely that their relatives
share many of these variants and that their genetic risks
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ant to communicate to the participants that it is likely
that such variants can be detected and that they may
have implications for other members of the family, and
that the consented individuals, or their parent may need
to communicate those results to other members of the
family.
Informed consent approach The informed consent
should include discussion of public deposition of data,
the entry of CLIA-validated results into medical records,
and the likely discovery of variants with implications for
family members.
Discussion
We describe an approach to the informed consent
process as a mutual opportunity for researchers and
participants to assess one another’s goals in MPS pro-
tocols that employ both hypothesis-generating and
hypothesis-testing methodologies. The use of MPS in
clinical research requires adaptation of established
processes of human subjects protections. The poten-
tially overwhelming scale of information generated by
MPS necessitates that investigators and IRBs adapt
traditional approaches to consent the subjects. Because
nearly all subjects will have a clinically actionable re-
sult, investigators must implement thoughtful plan for
consent regarding results disclosure, including setting
a threshold for the types of information that should
be disclosed to the participants.
While some of the informed consent issues for MPS
are independent of the study design, others should be
adapted based on whether the research study is
employing MPS to test a hypothesis (i.e., find the
cause of a rare condition in an affected cohort), or to
generate hypotheses (i.e., find deleterious or potentially
deleterious variants that warrant participant follow-up
and further investigation). For example, the health-
related attributes of the study cohort (healthy indivi-
duals versus disease patients) are likely to influence
participants’ motivations and expectations of MPS, and
in the case of a disease cohort create the need to
dichotomize the genetic variants into primary and sec-
ondary. Conversely, issues inherent to MPS technology
are central to the informed consent approach in both
types of studies. The availability of MPS allows a para-
digm shift in genetics research – no longer are investi-
gators constrained to long-standing approaches of
hypothesis-testing modes of research. The scale of
MPS allows investigators to proceed from genotype to
phenotype, and leads to new challenges for genetic
and medical counseling. Research participants receiving
results from MPS might not present with a personal
and/or family history suggestive of conditions revealedby their genotypic variants, and consequently might
not perceive their a priori risk to be elevated for those
conditions.
Participants’ motivations to have whole genome/
exome sequencing at this early stage are important to
take into consideration in the informed consent
process. Initial qualitative data suggest that individuals
enroll in the hypothesis-generating study because of al-
truism in promoting research, and a desire to learn
about genetic factors that contribute to their own
health and disease risk [23]. Most participants expect
that genomic information will improve the overall
knowledge of disease causes and treatments. Moreover,
data on research participants’ preferences to receive
different types of genetic results suggest that they have
strong intentions to receive all types of results [16].
However, they are able to discern between the types
and quality of information they could learn, and dem-
onstrate stronger attitudes to learn clinically actionable
and carrier status results when compared to results
that are uncertain or not clinically actionable. These
findings provide initial insights into the value these
early adopters place on information generated by high-
throughput sequencing studies, and help us tailor the
informed consent process to this group of individuals.
However, more empirical data are needed to guide the
informed consent process, including data on research
participants’ ability to receive results for multiple dis-
orders and traits.
Participants in both types of studies are engaged in a
discussion of the complex and dynamic nature of gen-
omic annotation so that they may make an informed de-
cision about participation and may be aware of the need
to revisit results learned at additional time points in the
future. As well, we advocate a process whereby investiga-
tors retain some latitude with respect to the most ser-
ious, potentially life-threatening mutations. While it is
mandatory to respect the autonomy of research subjects,
this does not mean that investigators must accede to the
research subject’s views of these “panic” results. In a
paradoxical way, the research participant and the re-
searcher can agree that the latter can maintain a small,
but initially ambiguous degree of latitude with respect to
these most serious variants. In the course of utilizing
MPS technology for further elucidation of the genetic
architecture of health and disease, it is imperative that
research participants and researchers be engaged in a
continuous discussion about the state of scientific know-
ledge and the types of information that could potentially
be learned from MPS. Although resource-intensive, this
“partnership model” [2] or informed cohort approach to
informed consent promotes respect for participants, and
allows evaluation of the benefits and harms of disclosure
in a more timely and relevant manner.
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We have here proposed a categorization of massively-
parallel clinical genomics research studies as hypothesis-
testing versus hypothesis-generating to help clarify the
issue of so-called incidental or secondary results for
the consent process, and aid the communication of
the research goals to study participants. By using this
categorization approach and considering seven import-
ant features of this kind of research (Primary versus
secondary variant results and the open-ended nature
of clinical genomics, Volume and nature of informa-
tion, Return of individual genotype results, Duty to
warn, Length of researcher and participant interaction,
Target population, and Privacy and confidentiality)
researchers can design an informed consent process
that is open, transparent, and appropriately balances
risks and benefits of this exciting approach to heritable
disease research.
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